From insulin to life-saving medical devices to last-ditch efforts to protect premature infants (including those from “live birth” abortions), multiple rules posted by the Health and Human Services Department in the final days of Donald Trump’s presidency are subject to a 60-day pause.
The halt on Trump-era rulemaking includes two controversial rules designed to curb high drug prices—one that changes the way pharmacy liaisons and drugmakers can pay each other and another that ties Medicare rates for expensive drugs to the prices paid in other countries.
A Wednesday memo circulated by White House Chief of Staff Ronald Klain said all ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.